Pancreatic cancer;Cancer du pancréas

Cancer/Radiotherapie

Volumn 14, Issue SUPPL. 1, 2010, Pages

  Huguet, F ^a   Orthuon, A ^a   Touboul, E ^a   Marseguerra, R ^a   Mornex, F ^b  

^a HÔPITAL TENON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Atlas; Conformal radiotherapy; Pancreatic cancer; Target volumes

Indexed keywords

GEMCITABINE;

ANATOMY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; FRANCE; HUMANS; NEOPLASM METASTASIS; PANCREAS; PANCREATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RECURRENCE; SURVIVAL RATE; TIME FACTORS;

EID: 78649783658     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(10)70012-3     Document Type: Article

References (35)

1. Exocrine pancreas. AJCC Cancer Staging Manual 2002, American Joint Committee on Cancer, Springer, New York, 157-64. 6th edition Ed.
2. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008, 56:159-175.
3. Brown M.W., Ning H., Arora B., Albert P.S., Poggi M., Camphausen K., et al. A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:274-283.
4. Bussels B., Goethals L., Feron M., Bielen D., Dymarkowski S., Suetens P., et al. Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol 2003, 68:69-74.
5. Chauffert B., Mornex F., Bonnetain F., Rougier P., Mariette C., Bouche O., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599.
6. Claude L., Mornex F., Khodri M. Cancers du pancréas. Techniques d'irradiation des cancers 2005, 300-307. Maloine, Paris. J.J. Mazeron, A. Maugis, C. Barret, F. Mornex (Eds.).
7. Evans D.B., Varadhachary G.R., Crane C.H., Sun C.S., Lee J.E., Pisters P.W., et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3496-3502.
8. Feng M., Balter J.M., Normolle D., Adusumilli S., Cao Y., Chenevert T.L., et al. Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys 2009, 74:884-891.
9. Gold E.B., Goldin S.B. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998, 7:67-91.
10. Goldstein D., Van Hazel G., Walpole E., Underhill C., Kotasek D., Michael M., et al. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 2007, 97:464-471.
11. Guérin S., Hill C. L'épidémiologie des cancers en France en 2010: comparaison avec les États-Unis. Bull Cancer 2010, 97:47-54.
12. Gwynne S., Wills L., Joseph G., John G., Staffurth J., Hurt C., et al. Respiratory movement of upper abdominal organs and its effect on radiotherapy planning in pancreatic cancer. Clin Oncol 2009, 21:713-719.
13. Hruban R.H., Petersen G.M., Goggins M., Tersmette A.C., Offerhaus G.J., Falatko F., et al. Familial pancreatic cancer. Ann Oncol 1999, 10:69-73.
14. Huguet F., Andre T., Hammel P., Artru P., Balosso J., Selle F., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
15. Huguet F., Girard N., Guerche C.S., Hennequin C., Mornex F., Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009, 27:2269-2277.
16. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903.
17. Klinkenbijl J.H., Jeekel J., Sahmoud T., van Pel R., Couvreur ml., Veenhof C.H., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999, 230:82-84. 776-82;discussion.
18. Ko A.H., Quivey J.M., Venook A.P., Bergsland E.K., Dito E., Schillinger B., et al. A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2007, 68:809-816.
19. Krishnan S., Rana V., Janjan N.A., Varadhachary G.R., Abbruzzese J.L., Das P., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55.
20. Le Scodan R., Mornex F., Girard N., Mercier C., Valette P.J., Ychou M., et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFROFFCD 9704 trial and literature review. Ann Oncol 2009, 20:1387-1396.
21. Loehrer P.J., Powell M.E., Cardenes H.R., Wagner L., Brell J.M., Ramanathan R.K., et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localiezd, unresectable pancreatic cancer: E4201. J Clin Oncol 2008, 26:4506.
22. Murphy J.D., Adusumilli S., Griffith K.A., Ray M.E., Zalupski mm., Lawrence T.S., et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808.
23. Neoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001, 358:1576-1585.
24. Neoptolemos J., Buchler M., Stocken D.D., Ghaneh P., Smith D., Bassi C., et al. ESPAC-3 (v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2009, 27. LBA4505.
25. Oettle H., Post S., Neuhaus P., Gellert K., Langrehr J., Ridwelski K., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007, 297:267-277.
26. Regine W.F., Winter K.A., Abrams R.A., Safran H., Hoffman J.P., Konski A., et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008, 299:1019-1026.
27. Rouvière H., Delmas A. Le pancréas. Anatomie humaine, tome 2: Tronc 1978, Masson, Paris.
28. Stocken D.D., Buchler M.W., Dervenis C., Bassi C., Jeekel H., Klinkenbijl J.H., et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005, 92:1372-1381.
29. Sultana A., Tudur Smith C., Cunningham D., Starling N., Tait D., Neoptolemos J.P., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007, 96:1183-1190.
30. Guide des procédures de radiothérapie externe 2007. Cancer Radiother 2008, 12:143-313. Société Française de Radiothérapie Oncologique.
31. Talamonti M.S., Small W., Mulcahy M.F., Wayne J.D., Attaluri V., Colletti L.M., et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006, 13:150-158.
32. van der Geld Y.G., van Triest B., Verbakel W.F., van Sornsen de Koste J.R., Senan S., Slotman B.J., et al. Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2008, 72:1215-1220.
33. Van Laethem J.L., Mornex F., Azria D., van Tienhoven G., Mauer M., Praet M., et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiation after curative resection for pancreatic cancer: Updated results of a randomized EORTC/FFCD/GERCOR phase II study (40013-22012/9203). J Clin Oncol 2009, 27:4527. (Meeting Abstracts).
34. Varadhachary G.R., Wolff R.A., Crane C.H., Sun C.S., Lee J.E., Pisters P.W., et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008, 26:3487-3495.
35. Yip D., Karapetis C., Strickland A., Steer C.B., Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. The Cochrane Library 2007, 4:1-72.